Trial
NCT02718300
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Incyte Corporation
Collaborators
—
Condition
MPN (Myeloproliferative Neoplasms)
Intervention
Parsaclisib
Why stopped
A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-01